-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Daxiong Pharmaceutical announced that it has signed a license agreement with Haini Pharmaceuticals, a subsidiary of Yangtze River Pharmaceutical Group, authorizing the latter to develop and sell its gastroesophageal reflux treatment drug fexuprazan in China.
According to the agreement, Haini Pharmaceuticals will be responsible for the clinical development of fexuprazan for the treatment of digestive system diseases, and will be responsible for the entire approval process of the drug in China.
It is reported that as a new generation of proton pump inhibitor, fexuprazan can reversibly block the proton pump secreting gastric acid for the treatment of gastroesophageal reflux disease.